Physicians' Academy for Cardiovascular Education

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD - Copenhagen, Denmark

Video navigation menu

  • Introduction to GLP-1 00:23
  • Mechanisms for CVD and CKD risk reduction 02:20
  • Effects on glycemia 02:52
  • Effects on body weight 04:13
  • Effects on blood pressure 05:42
  • Effects on blood lipids 07:53
  • Other potential mechanisms 08:49
  • Renal outcomes in large trials 09:41

Transcript

Show transcript

Educational information

This lecture by Filip Knop was part of the EBAC-accredited symposium "Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA" held during the ERA 2022 congress.

Faculty

Filip Krag Knop, MD, PhD, Professor of endocrinology and Director of Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Denmark.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Click here for the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: